Neulasta (Pegfilgrastim) and Biosimilar Market Size, Share, Growth, and Industry Analysis, By Type (Brand, Biosimilar), By Application (Hospital, Pharmacy, Other), Regional Insights and Forecast to 2035

Neulasta (Pegfilgrastim) and Biosimilar Market Overview

Neulasta (Pegfilgrastim) and Biosimilar Market size is estimated at USD 3259.44 million in 2026, set to expand to USD 5631.94 million by 2035, growing at a CAGR of 6.27%.

The Neulasta (Pegfilgrastim) and Biosimilar Market is expanding steadily due to the increasing global burden of cancer and rising chemotherapy procedures across hospitals and oncology centers. Pegfilgrastim products are widely used to reduce febrile neutropenia risk among cancer patients receiving myelosuppressive chemotherapy. More than 19 million new cancer cases were reported globally, while over 10 million cancer-related deaths increased demand for supportive oncology therapies. Biosimilar adoption is accelerating due to patent expirations and payer pressure for cost-efficient biologics. More than 60% of oncology treatment centers in developed economies now include pegfilgrastim biosimilars in treatment protocols. The Neulasta (Pegfilgrastim) and Biosimilar Market Report highlights strong demand from hospitals, specialty clinics, and ambulatory infusion centers.

The United States dominates the Neulasta (Pegfilgrastim) and Biosimilar Market due to high cancer incidence, advanced biologics infrastructure, and favorable reimbursement systems. More than 1.9 million new cancer cases are diagnosed annually in the country, while chemotherapy utilization exceeds 65% among oncology patients. Biosimilar penetration in supportive cancer care crossed 45% in major hospital systems. Around 70% of oncology clinics in the U.S. now prescribe pegfilgrastim biosimilars alongside branded products. The U.S. FDA has approved multiple pegfilgrastim biosimilars, increasing competition and improving patient access. The Neulasta (Pegfilgrastim) and Biosimilar Industry Analysis shows strong procurement activity from integrated healthcare networks and oncology group purchasing organizations.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 68% of chemotherapy patients receiving myelosuppressive treatment require granulocyte colony-stimulating factor support, while pegfilgrastim usage in oncology supportive care protocols exceeds 72% across major cancer treatment facilities.
• Major Market Restraint: Nearly 41% of healthcare providers reported biosimilar substitution concerns, while around 36% of oncology specialists cited interchangeability and prescribing hesitation affecting adoption rates in emerging healthcare systems.
• Emerging Trends: Approximately 58% of oncology procurement contracts now prioritize biosimilar pegfilgrastim products, while on-body injector utilization increased by 39% among outpatient chemotherapy administration settings worldwide.
• Regional Leadership: North America accounts for nearly 47% of global pegfilgrastim utilization, while Europe contributes approximately 29% due to strong biosimilar acceptance and hospital-driven oncology treatment programs.
• Competitive Landscape: More than 55% of market participation is controlled by top biologics manufacturers, while biosimilar entrants increased competitive pricing pressure by nearly 34% across institutional oncology procurement channels.
• Market Segmentation: Hospital pharmacies contribute approximately 52% of product distribution, while biosimilar pegfilgrastim products account for nearly 49% of supportive oncology biologics utilization across developed healthcare markets.
• Recent Development: Around 44% of newly signed oncology supply agreements now include biosimilar pegfilgrastim products, while automated injector adoption in chemotherapy clinics rose by nearly 31% during recent procurement cycles.

Neulasta (Pegfilgrastim) and Biosimilar Market Latest Trends

The Neulasta (Pegfilgrastim) and Biosimilar Market Trends indicate strong momentum toward biosimilar conversion across oncology care networks. More than 50% of large hospital procurement programs have shifted from branded pegfilgrastim to biosimilar alternatives. Oncology clinics are increasingly adopting value-based purchasing strategies, while nearly 46% of healthcare systems now include biosimilars in preferred treatment formularies. Increased awareness regarding supportive oncology care has also improved demand for long-acting granulocyte colony-stimulating factor therapies. The Neulasta (Pegfilgrastim) and Biosimilar Market Research Report highlights increased physician confidence in biosimilar safety, efficacy, and therapeutic equivalence.

Another important trend in the Neulasta (Pegfilgrastim) and Biosimilar Industry Report is the growing use of wearable drug delivery systems and on-body injectors. Nearly 38% of outpatient chemotherapy patients prefer automated delivery solutions due to convenience and reduced hospital visits. Digital monitoring integration in oncology drug administration also increased by 27% in specialty infusion centers. Biosimilar manufacturers are investing heavily in patient support programs, cold-chain optimization, and oncology partnerships. The Neulasta (Pegfilgrastim) and Biosimilar Market Forecast shows continued expansion in hospital pharmacy contracts, retail specialty pharmacy distribution, and ambulatory cancer care adoption.

Neulasta (Pegfilgrastim) and Biosimilar Market Dynamics

DRIVER

"Rising Global Cancer Incidence and Chemotherapy Utilization"

The increasing prevalence of cancer remains the primary growth driver for the Neulasta (Pegfilgrastim) and Biosimilar Market Size. More than 70% of chemotherapy regimens carry neutropenia risk, increasing demand for granulocyte colony-stimulating factor therapies. Hospitals and oncology treatment centers are expanding supportive care programs due to rising patient volumes. Nearly 63% of breast cancer and lung cancer patients receiving chemotherapy require neutropenia prevention therapies during treatment cycles. The growing elderly population further contributes to demand, as cancer incidence among individuals above 65 years exceeds 55% globally. Biosimilar adoption has also increased significantly, with over 48% of institutional oncology procurement contracts now favoring lower-cost pegfilgrastim alternatives. Government healthcare programs and private insurance providers continue supporting biosimilar utilization to reduce biologic therapy expenditure. 

RESTRAINTS

"Physician Hesitation and Biosimilar Switching Concerns"

Despite strong market penetration, the Neulasta (Pegfilgrastim) and Biosimilar Market faces restraints related to physician hesitation regarding biosimilar substitution and interchangeability. Nearly 37% of oncologists in developing regions remain cautious about switching stable patients from branded biologics to biosimilars. Concerns regarding immunogenicity, therapeutic consistency, and patient outcomes continue influencing prescribing decisions. Around 33% of smaller oncology practices still prefer established branded pegfilgrastim products due to long-term clinical familiarity. Regulatory variations across countries also create commercialization barriers for biosimilar manufacturers. In several emerging markets, biosimilar approval pathways remain inconsistent, delaying product launches and market entry. Cold-chain logistics challenges further affect supply continuity, especially in rural and low-resource healthcare systems. 

OPPORTUNITY

"Expansion of Biosimilar Adoption in Emerging Healthcare Markets"

The Neulasta (Pegfilgrastim) and Biosimilar Market Opportunities are increasing rapidly due to expanding healthcare infrastructure and rising biosimilar awareness in emerging economies. Countries across Asia-Pacific, Latin America, and the Middle East are strengthening oncology treatment programs and increasing biologic accessibility. More than 52% of newly established cancer treatment centers in emerging markets now include biosimilar supportive care therapies in procurement plans. Government initiatives supporting affordable cancer care are driving institutional demand for pegfilgrastim biosimilars. Oncology patient populations in developing economies continue increasing due to aging demographics, urbanization, and lifestyle-related cancer risk factors. Retail specialty pharmacies and hospital networks are expanding biosimilar distribution capabilities to improve treatment accessibility. The Neulasta (Pegfilgrastim) and Biosimilar Market Outlook also highlights opportunities in homecare oncology services and wearable injector technologies. Approximately 35% of chemotherapy patients now prefer outpatient or home-based supportive care administration. 

CHALLENGE

"Intense Pricing Pressure and Competitive Biologics Environment"

The Neulasta (Pegfilgrastim) and Biosimilar Market Challenges are strongly linked to aggressive pricing competition and increasing market saturation. Multiple biosimilar entrants have intensified price reductions across hospital procurement contracts and oncology group purchasing agreements. Nearly 43% of institutional buyers prioritize lowest-cost procurement strategies, creating pressure on manufacturers to reduce prices continuously. Smaller biosimilar developers face operational difficulties due to high biologics manufacturing costs and stringent regulatory compliance requirements. Maintaining stable production quality, cold-chain integrity, and pharmacovigilance systems requires substantial long-term investment. Around 31% of biosimilar manufacturers reported supply chain disruptions affecting production schedules and distribution timelines. Competitive differentiation also remains difficult because many pegfilgrastim biosimilars demonstrate similar therapeutic profiles and delivery mechanisms. 

Neulasta (Pegfilgrastim) and Biosimilar Market Segmentation

The Neulasta (Pegfilgrastim) and Biosimilar Market Segmentation is categorized by type and application, reflecting growing adoption across oncology treatment environments. By type, the market is divided into branded pegfilgrastim products and biosimilars, with biosimilars gaining strong acceptance due to affordability and wider hospital procurement. By application, the market includes hospitals, pharmacies, and other healthcare settings such as specialty oncology centers and ambulatory infusion clinics. More than 62% of pegfilgrastim demand originates from institutional oncology treatment facilities, while pharmacy-based dispensing continues expanding because of increasing outpatient chemotherapy treatment programs globally.

Download Free Sample to learn more about this report.

BY TYPE

Brand: Branded pegfilgrastim products continue to maintain a substantial position in the Neulasta (Pegfilgrastim) and Biosimilar Market Share due to strong physician familiarity, established clinical usage, and long-term oncology treatment integration. More than 54% of oncology specialists in premium healthcare institutions continue prescribing branded formulations for high-risk chemotherapy patients. Large hospital systems and comprehensive cancer centers often prefer branded products because of existing procurement contracts and confidence in therapeutic consistency. Around 48% of supportive oncology treatment guidelines in developed healthcare markets still reference branded pegfilgrastim products as preferred therapy options for severe neutropenia prevention. On-body injector technologies associated with branded products are also contributing to sustained utilization, with nearly 37% of outpatient chemotherapy patients preferring automated administration devices. 

Biosimilar: Biosimilar pegfilgrastim products are rapidly expanding across the Neulasta (Pegfilgrastim) and Biosimilar Market Growth landscape due to increasing healthcare cost optimization strategies and broader regulatory approvals. Nearly 49% of institutional oncology procurement contracts now include biosimilar pegfilgrastim products as first-line supportive care options. Hospitals and payer organizations are aggressively promoting biosimilar conversion programs, while approximately 57% of oncology purchasing groups prioritize lower-cost biologic alternatives during contract negotiations. Physician confidence in biosimilar efficacy and safety has increased significantly, with more than 61% of oncology specialists reporting positive treatment outcomes comparable to reference biologics. Biosimilar utilization has grown strongly within outpatient chemotherapy clinics and regional cancer treatment networks where affordability remains a critical factor. 

BY APPLICATION

Hospital: Hospitals represent the leading application segment in the Neulasta (Pegfilgrastim) and Biosimilar Market Size because of high chemotherapy patient volumes and centralized oncology treatment infrastructure. More than 58% of pegfilgrastim administrations occur within hospital-based oncology departments and integrated cancer care facilities. Large multispecialty hospitals utilize pegfilgrastim therapies extensively for breast cancer, lung cancer, colorectal cancer, and hematologic malignancy treatment protocols. Around 66% of neutropenia prevention therapies are initiated directly within institutional oncology infusion centers. Hospital pharmacies are also increasing biosimilar procurement to reduce biologic therapy expenditure while maintaining treatment continuity for chemotherapy patients. The Neulasta (Pegfilgrastim) and Biosimilar Market Report indicates that academic medical centers and tertiary care hospitals account for a significant proportion of supportive oncology biologics utilization. 

Pharmacy: Pharmacies are becoming an increasingly important application segment within the Neulasta (Pegfilgrastim) and Biosimilar Industry Analysis due to rising outpatient chemotherapy and self-administration trends. Nearly 39% of pegfilgrastim prescriptions are now distributed through retail specialty pharmacies and oncology-focused pharmacy networks. Specialty pharmacies provide cold-chain handling, patient education, reimbursement assistance, and therapy coordination services for biologic supportive care treatments. Around 44% of oncology patients receiving outpatient chemotherapy prefer pharmacy-supported biologic dispensing because of reduced hospital visits and improved convenience. Biosimilar availability in pharmacy distribution channels has also expanded substantially, with more than 47% of specialty pharmacies including biosimilar pegfilgrastim products within preferred dispensing programs. 

Other: The “Other” application segment includes ambulatory infusion centers, specialty oncology clinics, homecare settings, and independent cancer treatment networks participating in the Neulasta (Pegfilgrastim) and Biosimilar Market Outlook. Nearly 24% of pegfilgrastim administration now occurs outside traditional hospital environments due to increasing adoption of outpatient oncology treatment models. Ambulatory infusion centers are expanding rapidly because they reduce inpatient treatment burden and improve chemotherapy scheduling flexibility. Approximately 35% of cancer patients undergoing moderate-risk chemotherapy receive supportive biologic therapies through independent oncology clinics. Homecare oncology support is also increasing, especially among elderly patients and individuals requiring reduced hospital exposure. The use of wearable pegfilgrastim delivery devices in homecare settings has increased by nearly 32%, improving treatment compliance and convenience. 

Neulasta (Pegfilgrastim) and Biosimilar Market Regional Outlook

The Neulasta (Pegfilgrastim) and Biosimilar Market Outlook demonstrates strong regional diversification driven by cancer prevalence, biosimilar adoption rates, and healthcare infrastructure expansion. North America accounts for nearly 47% of the global market share due to advanced oncology treatment systems and high biologic utilization. Europe contributes approximately 29% supported by favorable biosimilar regulations and centralized procurement programs. Asia-Pacific holds around 18% share with rapid growth in oncology care access and increasing biosimilar penetration. Middle East & Africa represent close to 6% share as regional healthcare modernization and cancer treatment investments continue expanding supportive biologic therapy adoption across major healthcare institutions.

Download Free Sample to learn more about this report.

NORTH AMERICA

North America dominates the Neulasta (Pegfilgrastim) and Biosimilar Market Share with approximately 47% contribution to global consumption. The region records high chemotherapy procedure volumes, with more than 68% of cancer patients receiving biologic supportive care therapies during treatment cycles. The United States accounts for the largest portion of regional demand due to strong insurance coverage, widespread oncology infrastructure, and early biosimilar approvals. Nearly 58% of oncology clinics across North America now include pegfilgrastim biosimilars within treatment formularies. Hospital-based biologic procurement remains highly organized, while more than 49% of integrated healthcare systems prioritize biosimilar conversion programs. Canada also contributes to regional expansion through public healthcare-supported oncology treatment access and biosimilar reimbursement initiatives. The Neulasta (Pegfilgrastim) and Biosimilar Market Analysis indicates that wearable drug delivery systems and outpatient chemotherapy programs continue driving regional demand growth.

EUROPE

Europe represents nearly 29% of the global Neulasta (Pegfilgrastim) and Biosimilar Market Size due to widespread biosimilar acceptance and strong regulatory support for biologic substitution. More than 63% of oncology hospitals across Western Europe have integrated pegfilgrastim biosimilars into standard supportive care treatment protocols. Germany, France, Italy, and the United Kingdom remain key contributors because of advanced cancer treatment infrastructure and centralized healthcare procurement systems. Approximately 54% of oncology biologic purchasing contracts in Europe now prioritize biosimilar inclusion. Physician awareness regarding biosimilar therapeutic equivalence has improved significantly, supporting broader patient adoption across regional healthcare systems. Eastern European countries are also increasing supportive oncology therapy utilization due to rising cancer incidence and improved biologic accessibility. The Neulasta (Pegfilgrastim) and Biosimilar Market Trends show that specialty pharmacy networks and ambulatory infusion centers are expanding rapidly throughout Europe, strengthening outpatient biologic therapy administration capabilities.

ASIA-PACIFIC

Asia-Pacific holds approximately 18% of the Neulasta (Pegfilgrastim) and Biosimilar Market Share and remains the fastest-expanding regional segment due to rising cancer burden and healthcare modernization. Countries including China, Japan, India, South Korea, and Australia are increasing oncology treatment investments and biosimilar manufacturing capabilities. Nearly 57% of newly established oncology centers in major Asia-Pacific economies now include pegfilgrastim biosimilars in procurement frameworks. Government-led healthcare reforms and local biologic production initiatives are improving treatment accessibility across urban and semi-urban regions. More than 46% of cancer treatment facilities in Asia-Pacific have adopted outpatient chemotherapy support programs using biosimilar granulocyte colony-stimulating factor therapies. Japan maintains strong demand for branded biologics, while China and India are experiencing rapid biosimilar penetration because of affordability-focused healthcare strategies. The Neulasta (Pegfilgrastim) and Biosimilar Market Forecast highlights increasing physician acceptance and growing oncology patient populations across the region.

MIDDLE EAST & AFRICA

Middle East & Africa contribute close to 6% of the global Neulasta (Pegfilgrastim) and Biosimilar Market Outlook, supported by improving oncology infrastructure and rising cancer awareness initiatives. Gulf countries are investing heavily in specialized cancer treatment hospitals and biologic procurement programs. Nearly 38% of tertiary healthcare facilities across the Middle East now utilize pegfilgrastim biosimilars within supportive oncology treatment pathways. South Africa remains a leading African contributor because of growing biologic therapy adoption and increasing chemotherapy treatment access. Around 29% of oncology clinics in the region have expanded outpatient supportive care capabilities using biosimilar products. Government-backed healthcare modernization projects and partnerships with global pharmaceutical manufacturers are improving biologic distribution networks. The Neulasta (Pegfilgrastim) and Biosimilar Industry Report indicates that increasing healthcare expenditure, improving diagnostic access, and expanding oncology workforce training programs are supporting gradual market expansion across the Middle East and Africa.

List of Key Neulasta (Pegfilgrastim) and Biosimilar Market Companies

• Amgen
• Viatris
• Coherus
• Novartis
• Pfizer
• Amneal Pharmaceutical
• Fresenius Kabi

Top Two Companies with Highest Share

• Amgen: Holds nearly 41% market presence due to strong branded pegfilgrastim adoption, advanced oncology distribution networks, and hospital procurement dominance.
• Novartis: Accounts for approximately 18% market participation supported by strong biosimilar penetration, oncology partnerships, and expanding international biologics accessibility programs.

Investment Analysis and Opportunities

The Neulasta (Pegfilgrastim) and Biosimilar Market Opportunities continue expanding as healthcare systems increase investment in affordable oncology supportive care therapies. Nearly 56% of institutional biologic procurement programs now prioritize biosimilar inclusion to reduce overall treatment costs and improve patient accessibility. Pharmaceutical manufacturers are increasing investment in biosimilar manufacturing capacity, cold-chain logistics, and regional oncology partnerships. More than 48% of biologic production expansion projects are focused on oncology supportive care products, including pegfilgrastim biosimilars. Emerging healthcare markets are also attracting strategic investment because cancer diagnosis rates and chemotherapy treatment volumes continue increasing steadily. Oncology-focused venture partnerships and biologics manufacturing collaborations are strengthening market competitiveness across Asia-Pacific and Latin America.

Investment activity is also increasing in advanced drug delivery systems and outpatient oncology support services. Nearly 37% of supportive oncology care investments are directed toward wearable injector technologies and homecare biologic administration programs. Healthcare providers are adopting digital patient monitoring systems to improve adherence and reduce hospital readmissions associated with chemotherapy-related neutropenia. Specialty pharmacy networks are expanding rapidly, with approximately 44% of oncology biologic distribution growth originating from pharmacy-supported outpatient treatment programs. The Neulasta (Pegfilgrastim) and Biosimilar Market Insights indicate that long-term investment opportunities remain strong in regional biosimilar manufacturing, physician education programs, and decentralized oncology treatment infrastructure.

New Products Development

The Neulasta (Pegfilgrastim) and Biosimilar Market Trends indicate strong innovation activity focused on biosimilar formulation improvement, wearable injectors, and patient-friendly administration systems. Nearly 42% of current product development programs involve enhanced biologic delivery technologies aimed at improving chemotherapy support convenience and adherence. Manufacturers are developing long-acting pegfilgrastim formulations with optimized stability profiles and simplified storage requirements. Around 35% of oncology clinics are increasing adoption of automated injector systems that allow patients to receive treatment outside hospital settings. Product developers are also investing in biosimilar comparability studies and advanced biologic analytics to improve physician confidence and strengthen regulatory approvals across global markets.

New product development strategies are increasingly centered on expanding oncology supportive care accessibility in emerging healthcare regions. Approximately 47% of biosimilar pipeline projects target cost-efficient manufacturing and scalable production systems to improve supply consistency. Pharmaceutical companies are also introducing integrated patient assistance programs and digital therapy management solutions to strengthen product differentiation. More than 31% of oncology biologic developers are collaborating with regional healthcare providers to improve patient education and biologic adoption. The Neulasta (Pegfilgrastim) and Biosimilar Market Research Report highlights growing interest in combination supportive care platforms and integrated oncology treatment pathways that improve chemotherapy tolerance and reduce neutropenia-related hospitalization rates.

Five Recent Developments

• Amgen expanded oncology support programs by increasing wearable injector distribution capacity by nearly 28%, improving outpatient pegfilgrastim administration efficiency across major chemotherapy treatment networks in 2025.
• Novartis strengthened biosimilar penetration through new hospital procurement agreements covering approximately 33% additional oncology treatment facilities across European and Asia-Pacific healthcare systems during 2025.
• Pfizer increased biosimilar production efficiency by approximately 26% through manufacturing optimization initiatives supporting broader pegfilgrastim supply continuity for institutional oncology procurement programs in 2025.
• Coherus expanded specialty pharmacy partnerships by nearly 31%, improving outpatient biologic accessibility and strengthening chemotherapy supportive care distribution capabilities throughout regional oncology networks in 2025.
• Fresenius Kabi enhanced cold-chain biologic logistics infrastructure with approximately 24% additional distribution capacity, improving pegfilgrastim biosimilar availability across emerging healthcare markets during 2025.

Report Coverage Of Neulasta (Pegfilgrastim) and Biosimilar Market

The Neulasta (Pegfilgrastim) and Biosimilar Market Report provides detailed analysis of market dynamics, segmentation, competitive landscape, regional outlook, investment activity, and emerging oncology supportive care trends. The report evaluates branded pegfilgrastim products and biosimilars across multiple healthcare environments, including hospitals, specialty pharmacies, ambulatory infusion centers, and homecare oncology settings. More than 62% of analyzed market demand originates from institutional chemotherapy treatment programs, while biosimilar adoption rates exceed 49% across advanced healthcare systems. The report also highlights physician prescribing behavior, procurement strategies, and biologic therapy accessibility trends.

The Neulasta (Pegfilgrastim) and Biosimilar Industry Analysis further examines regulatory developments, oncology infrastructure expansion, biosimilar manufacturing strategies, and regional competitive positioning. Approximately 57% of healthcare procurement organizations now prioritize biosimilar inclusion within oncology supportive care formularies. The report includes evaluation of wearable injector technologies, specialty pharmacy growth, decentralized cancer treatment models, and outpatient chemotherapy support trends. It also assesses market opportunities linked to emerging healthcare economies, increasing cancer prevalence, and expanding biologic treatment accessibility across global oncology care systems.